June 26, 2020 Rare diseases dominate catalysts for the smallest companies Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
February 13, 2019 Another knock back for urea cycle disorders Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
